Ratings Vital Healthcare Property Trust

Equities

VHP

NZCHPE0001S4

End-of-day quote New Zealand S.E. Other stock markets 2024-09-10			5-day change	1st Jan Change
1.975 ^NZD	+3.13%		-1.25%	-10.63%

08-08	Vital Healthcare Property Trust Announces Dividend Payable on 19 September 2024	CI
08-08	Vital Healthcare Property Trust Reports Earnings Results for the Full Year Ended June 30, 2024	CI

Summary: Vital Healthcare Property Trust

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Highlights: Vital Healthcare Property Trust

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company's share price in relation to its net book value makes it look relatively cheap.
This company will be of major interest to investors in search of a high dividend stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

Weaknesses: Vital Healthcare Property Trust

One of the major weak points of the company is its financial situation.
With an expected P/E ratio at 75.63 and 8.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings Chart: Vital Healthcare Property Trust

Source: Surperformance

ESG chart: Vital Healthcare Property Trust

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	VITAL HEALTHCARE PROPERTY TRUST				821M
	WELLTOWER INC.				78.59B
	VENTAS, INC.				26.84B
	HEALTHPEAK PROPERTIES, INC.				15.54B
	OMEGA HEALTHCARE INVESTORS, INC.				10.39B
	HEALTHCARE REALTY TRUST INCORPORATED				6.62B
	CARETRUST REIT, INC.				4.65B
	SABRA HEALTH CARE REIT, INC.				4.13B
	NATIONAL HEALTH INVESTORS, INC.				3.86B
	AEDIFICA SA				3.4B
	Average				15.48B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

D+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes